Plasma protein binding of zomepirac sodium.
The plasma protein binding of zomepirac, a new nonnarcotic analgesic, was studied using equilibrium dialysis. Experiments were performed using human plasma and plasma from mice, rats, and rhesus monkeys, all species of pharmacological or toxicological interest. At concentrations approximating those achieved in vivo, the binding was fairly constant at 98-99% in all species except the rhesus monkey, where binding was decreased from 98 to approximately 96% at higher concentrations (greater then 50 microgram/ml). Zomepirac (10 microgram/ml) did not appear to displace or to be displaced by warfarin (10 microgram/ml) caused a concentration-dependent decrease in zomepirac (10 microgram/ml) binding. Zomepirac did not affect salicylate binding.[1]References
- Plasma protein binding of zomepirac sodium. O'Neill, P.J. Journal of pharmaceutical sciences. (1981) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg